Simon Dearden
YOU?
Author Swipe
View article: The landscape of <scp><i>BRCA1</i></scp> and <scp><i>BRCA2</i></scp> large rearrangements in an international cohort of over 20 000 ovarian tumors identified using next‐generation sequencing
The landscape of <span><i>BRCA1</i></span> and <span><i>BRCA2</i></span> large rearrangements in an international cohort of over 20 000 ovarian tumors identified using next‐generation sequencing Open
Background Approximately half of ovarian tumors have defects within the homologous recombination repair pathway. Tumors carrying pathogenic variants (PVs) in BRCA1/BRCA2 are more likely to respond to poly‐ADP ribose polymerase (PARP) inhib…
View article: Data from Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and <i>BRCA1, BRCA2</i>, or <i>ATM</i> Alterations Identified by Testing Circulating Tumor DNA
Data from Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and <i>BRCA1, BRCA2</i>, or <i>ATM</i> Alterations Identified by Testing Circulating Tumor DNA Open
Purpose:The phase III PROfound study (NCT02987543) evaluated olaparib versus abiraterone or enzalutamide (control) in metastatic castration-resistant prostate cancer (mCRPC) with tumor homologous recombination repair (HRR) gene alterations…
View article: Supplementary Data from Detection of <i>BRCA1</i>, <i>BRCA2</i>, and <i>ATM</i> Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound
Supplementary Data from Detection of <i>BRCA1</i>, <i>BRCA2</i>, and <i>ATM</i> Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound Open
Supplementary Data from Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound
View article: Supplementary Figure from Detection of <i>BRCA1</i>, <i>BRCA2</i>, and <i>ATM</i> Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound
Supplementary Figure from Detection of <i>BRCA1</i>, <i>BRCA2</i>, and <i>ATM</i> Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound Open
Supplementary Figure from Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound
View article: Supplementary Figure from Detection of <i>BRCA1</i>, <i>BRCA2</i>, and <i>ATM</i> Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound
Supplementary Figure from Detection of <i>BRCA1</i>, <i>BRCA2</i>, and <i>ATM</i> Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound Open
Supplementary Figure from Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound
View article: Supplementary Figure from Detection of <i>BRCA1</i>, <i>BRCA2</i>, and <i>ATM</i> Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound
Supplementary Figure from Detection of <i>BRCA1</i>, <i>BRCA2</i>, and <i>ATM</i> Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound Open
Supplementary Figure from Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound
View article: Data from Detection of <i>BRCA1</i>, <i>BRCA2</i>, and <i>ATM</i> Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound
Data from Detection of <i>BRCA1</i>, <i>BRCA2</i>, and <i>ATM</i> Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound Open
Purpose:Not all patients with metastatic castration-resistant prostate cancer (mCRPC) have sufficient tumor tissue available for multigene molecular testing. Furthermore, samples may fail because of difficulties within the testing procedur…
View article: Supplementary Data from Detection of <i>BRCA1</i>, <i>BRCA2</i>, and <i>ATM</i> Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound
Supplementary Data from Detection of <i>BRCA1</i>, <i>BRCA2</i>, and <i>ATM</i> Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound Open
Supplementary Data from Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound
View article: Supplementary Figure from Detection of <i>BRCA1</i>, <i>BRCA2</i>, and <i>ATM</i> Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound
Supplementary Figure from Detection of <i>BRCA1</i>, <i>BRCA2</i>, and <i>ATM</i> Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound Open
Supplementary Figure from Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound
View article: Data from Detection of <i>BRCA1</i>, <i>BRCA2</i>, and <i>ATM</i> Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound
Data from Detection of <i>BRCA1</i>, <i>BRCA2</i>, and <i>ATM</i> Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound Open
Purpose:Not all patients with metastatic castration-resistant prostate cancer (mCRPC) have sufficient tumor tissue available for multigene molecular testing. Furthermore, samples may fail because of difficulties within the testing procedur…
View article: Supplementary Figure from Detection of <i>BRCA1</i>, <i>BRCA2</i>, and <i>ATM</i> Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound
Supplementary Figure from Detection of <i>BRCA1</i>, <i>BRCA2</i>, and <i>ATM</i> Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound Open
Supplementary Figure from Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound
View article: Supplementary Figure from Detection of <i>BRCA1</i>, <i>BRCA2</i>, and <i>ATM</i> Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound
Supplementary Figure from Detection of <i>BRCA1</i>, <i>BRCA2</i>, and <i>ATM</i> Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound Open
Supplementary Figure from Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound
View article: Supplementary Figure from Detection of <i>BRCA1</i>, <i>BRCA2</i>, and <i>ATM</i> Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound
Supplementary Figure from Detection of <i>BRCA1</i>, <i>BRCA2</i>, and <i>ATM</i> Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound Open
Supplementary Figure from Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound
View article: Supplementary Figure from Detection of <i>BRCA1</i>, <i>BRCA2</i>, and <i>ATM</i> Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound
Supplementary Figure from Detection of <i>BRCA1</i>, <i>BRCA2</i>, and <i>ATM</i> Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound Open
Supplementary Figure from Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound
View article: Supplementary Tables S1-S2 from Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and <i>BRCA1, BRCA2</i>, or <i>ATM</i> Alterations Identified by Testing Circulating Tumor DNA
Supplementary Tables S1-S2 from Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and <i>BRCA1, BRCA2</i>, or <i>ATM</i> Alterations Identified by Testing Circulating Tumor DNA Open
Supplementary data presenting additional demographic data and safety analysis.
View article: Supplementary Tables S1-S2 from Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and <i>BRCA1, BRCA2</i>, or <i>ATM</i> Alterations Identified by Testing Circulating Tumor DNA
Supplementary Tables S1-S2 from Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and <i>BRCA1, BRCA2</i>, or <i>ATM</i> Alterations Identified by Testing Circulating Tumor DNA Open
Supplementary data presenting additional demographic data and safety analysis.
View article: Supplementary Data from Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer
Supplementary Data from Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer Open
Suplement_Tracked changes
View article: Supplementary Figure 4 from Identification of a Subset of Human Non–Small Cell Lung Cancer Patients with High PI3Kβ and Low PTEN Expression, More Prevalent in Squamous Cell Carcinoma
Supplementary Figure 4 from Identification of a Subset of Human Non–Small Cell Lung Cancer Patients with High PI3Kβ and Low PTEN Expression, More Prevalent in Squamous Cell Carcinoma Open
PDF file - 129K, Reduced nuclear PTEN in SCC compared with AC (TMA Set 2).
View article: Supplementary Figure 3 from Identification of a Subset of Human Non–Small Cell Lung Cancer Patients with High PI3Kβ and Low PTEN Expression, More Prevalent in Squamous Cell Carcinoma
Supplementary Figure 3 from Identification of a Subset of Human Non–Small Cell Lung Cancer Patients with High PI3Kβ and Low PTEN Expression, More Prevalent in Squamous Cell Carcinoma Open
PDF file - 133K,Reduced nuclear PTEN in SCC compared with AC (TMA Set 1).
View article: Supplementary Figure 4 from Identification of a Subset of Human Non–Small Cell Lung Cancer Patients with High PI3Kβ and Low PTEN Expression, More Prevalent in Squamous Cell Carcinoma
Supplementary Figure 4 from Identification of a Subset of Human Non–Small Cell Lung Cancer Patients with High PI3Kβ and Low PTEN Expression, More Prevalent in Squamous Cell Carcinoma Open
PDF file - 129K, Reduced nuclear PTEN in SCC compared with AC (TMA Set 2).
View article: Table S4 from Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer
Table S4 from Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer Open
Table S4 shows a comparison of central cobas tissue and baseline cobas plasma test results for EGFR-TKI sensitizing mutations (All screened patients)
View article: Data from Identification of a Subset of Human Non–Small Cell Lung Cancer Patients with High PI3Kβ and Low PTEN Expression, More Prevalent in Squamous Cell Carcinoma
Data from Identification of a Subset of Human Non–Small Cell Lung Cancer Patients with High PI3Kβ and Low PTEN Expression, More Prevalent in Squamous Cell Carcinoma Open
Purpose: The phosphoinositide 3-kinase (PI3K) pathway is a major oncogenic signaling pathway and an attractive target for therapeutic intervention. Signaling through the PI3K pathway is moderated by the tumor suppressor PTEN, which is defi…
View article: Supplementary Figure 1 from Identification of a Subset of Human Non–Small Cell Lung Cancer Patients with High PI3Kβ and Low PTEN Expression, More Prevalent in Squamous Cell Carcinoma
Supplementary Figure 1 from Identification of a Subset of Human Non–Small Cell Lung Cancer Patients with High PI3Kβ and Low PTEN Expression, More Prevalent in Squamous Cell Carcinoma Open
PDF file - 145K, Isoform specificity of PI3Kbeta antibody (AGG4888).
View article: Supplementary Data from Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer
Supplementary Data from Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer Open
Suplement_Tracked changes
View article: Table S3 from Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer
Table S3 from Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer Open
Table S3 shows the numbers of patients with discordant EGFR mutation test results
View article: Supplementary Data from Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer
Supplementary Data from Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer Open
Supplement_Clean version
View article: Table S2 from Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer
Table S2 from Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer Open
Table S2 shows the categorization of local testing methods based on assay limit of detection compared to the cobas® EGFR Mutation Test v2
View article: Supplementary Figure 3 from Identification of a Subset of Human Non–Small Cell Lung Cancer Patients with High PI3Kβ and Low PTEN Expression, More Prevalent in Squamous Cell Carcinoma
Supplementary Figure 3 from Identification of a Subset of Human Non–Small Cell Lung Cancer Patients with High PI3Kβ and Low PTEN Expression, More Prevalent in Squamous Cell Carcinoma Open
PDF file - 133K,Reduced nuclear PTEN in SCC compared with AC (TMA Set 1).